CBP 1018
Alternative Names: CBP-1018Latest Information Update: 02 Jan 2025
At a glance
- Originator Coherent Biopharma (Suzhou)
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 13 Sep 2024 Phase-I development is ongoing in China (IV, Injection)
- 13 Sep 2024 Efficacy and safety data from a phase Ia/Ib trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 31 May 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)